Skip to main content
In-Vitro Research Only
Sign in

B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research

The Scientific Advisory Board4th Sep 2026

B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research
AT A GLANCE · KEY RESEARCH SUMMARY

What You Need to Know About B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research

Primary Focus
B7-33 is a synthetic single-chain peptide designed as a functional selective agonist for the relaxin family peptide receptor 1 (RXFP1), primarily investigated in laboratory models of fibrosis and tissue remodelling.
Molecular Profile
A 27-amino-acid single-chain peptide fragment derived from the B-chain of human H2 relaxin (Molecular Weight: approximately 3,234.8 Daltons).
Fridge Storage
2°C–8°C (12–24 Months)
Quality Standard
99%+ HPLC Verified
  • Researchers study B7-33 because it is a simplified, single-chain version of the complex two-chain H2 relaxin hormone, making it far easier and more economical to synthesise for laboratory work.
  • It binds to the RXFP1 receptor and selectively triggers the pERK1/2 signalling pathway to boost matrix metalloproteinase-2 (MMP-2) production, which helps break down excess collagen.
  • Unlike native H2 relaxin, B7-33 minimally activates the cAMP pathway in specific cell types, meaning it avoids promoting unwanted tumour growth in preclinical models of prostate and breast cancer.
  • Published rodent studies have observed that B7-33 reduces scar tissue build-up in the heart, lungs, and kidneys while supporting normal organ function.

How B7-33 Unlocks Relaxin-2 Receptor Signalling Without the Baggage

B7-33 is a synthetic single-chain peptide that selectively activates the relaxin-2 receptor (RXFP1) to clear excess scar tissue without triggering unwanted cell growth. By flipping the anti-fibrotic switch while leaving the cAMP growth pathway idle, it gives scientists a clean way to study tissue remodelling and blood vessel elasticity.

To see why B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research matters so much in modern laboratories, it helps to look at native human relaxin-2 first. Natural relaxin-2 is a two-chain hormone famous for softening connective tissue and helping blood vessels relax. When tissues suffer damage, specialized cells called fibroblasts often go into overdrive, laying down thick sheets of collagen. This process creates stiff, fibrous scarring in organs like the heart, lungs, and kidneys. Native relaxin-2 tells the body to produce matrix metalloproteinases—natural enzymes that chew through that stiff collagen web and restore normal tissue flexibility.

However, native relaxin-2 has two major drawbacks in laboratory models. First, because it consists of two separate amino acid chains held together by three disulfide bridges, it is expensive and tricky to synthesise. Second, when native relaxin-2 binds to the RXFP1 receptor, it turns on two different internal signals at the same time: the pERK1/2 pathway, which breaks down scar tissue, and the cAMP pathway, which can encourage rapid cell division and tumour progression in certain prostate and breast cancer cell lines.

Researchers at the Florey Institute solved both problems by isolating just the active B-chain of relaxin-2 and modifying its tail end to keep it soluble. The result is B7-33. When B7-33 binds to RXFP1, it exhibits what biochemists call functional selectivity. In plain English, it pushes the receptor just enough to fire up the beneficial pERK1/2 enzyme pathway for collagen turnover, while barely touching the cAMP switch. Even better, B7-33 shows a strong preference for cells called myofibroblasts—the exact cells responsible for laying down scar tissue—because those cells naturally express both RXFP1 and a helper receptor called AT2R.

RELATED UK CATALOGUE

B7-33 is not stocked as its own vial. For relaxin-receptor and fibrosis research, the closest stocked materials are the BPC-157 & TB-500 blend and GHK-Cu.

Browse Full UK Peptide Catalogue →

What Published Studies Observe Across Early and Late Timelines

When scientists introduce B7-33 into cell cultures or preclinical models, the observed responses unfold in two clear phases: rapid intracellular signalling followed by slower, structural tissue remodelling. Understanding this split helps researchers set realistic observation windows for their experiments.

During the first five to sixty minutes after exposure in cell culture, the immediate biochemical events take place. Once a measured level of B7-33 docks onto the RXFP1-AT2R receptor complex on the surface of a myofibroblast, phosphorylation of extracellular signal-regulated kinase (pERK1/2) spikes sharply. Within the first few hours, this signal travels into the cell nucleus and turns down the expression of transforming growth factor-beta 1 (TGF-B1), the primary chemical messenger that orders cells to build scar tissue. Simultaneously, nitric oxide synthase activity rises in endothelial cells, leading to measurable vasodilation and reduced vascular resistance within the first twenty-four hours of observation.

Structural tissue remodelling takes much longer because the cells have to physically manufacture enzymes, secrete them into the extracellular matrix, and digest dense collagen fibres. In published rodent models of cardiac and pulmonary fibrosis, researchers typically monitor subjects over a fourteen-to-twenty-eight-day window. By the end of the first week, laboratory assays show a clear uptick in matrix metalloproteinase-2 (MMP-2) levels. Between weeks two and four, histological staining reveals a visible reduction in interstitial collagen deposition compared to untreated control groups. In models examining blood vessel stiffness and cardiac output, measurable improvements in left ventricular compliance and arterial elasticity generally appear around the two-to-three-week mark.

Importantly, when researchers extended these preclinical studies up to eight weeks in prostate tumour xenograft models, high study amounts of B7-33 did not accelerate tumour growth—directly contrasting with native relaxin-2, which promoted mass expansion over the exact same timeframe.

Mechanism Brief: B7-33 is a biased RXFP1 agonist that activates the pERK1/2 anti-fibrotic enzyme pathway while bypassing the cAMP cascade linked to tumour promotion. This single-chain structure gives researchers all the collagen-clearing benefits of native relaxin-2 without the complex synthesis or oncogenic risk.

Structural and Functional Comparison: B7-33 vs Native H2 Relaxin

CharacteristicB7-33 PeptideNative H2 Relaxin (Serelaxin)
Molecular StructureSingle-chain peptide (27 amino acids)Two-chain peptide (A and B chains, 53 amino acids) linked by three disulfide bonds
Synthesis ComplexitySimple, high-yield solid-phase synthesisComplex, expensive multi-step folding and recombinant production
Primary Receptor TargetRXFP1 (Relaxin Family Peptide Receptor 1)RXFP1 (with cross-reactivity at RXFP2 in high concentrations)
Dominant Signalling PathwayBiased toward pERK1/2 activation over cAMP in fibroblastsActivates both cAMP and pERK1/2 pathways strongly
Anti-Fibrotic ActivityPromotes MMP-2 expression and collagen degradation in laboratory modelsPromotes MMP expression and reduces collagen deposition
Oncogenic Profile in Preclinical ModelsDid not promote tumour growth in rodent prostate and breast cancer modelsAssociated with increased tumour vascularisation and growth at high study amounts

Complementary Peptides Studied Alongside B7-33 for Tissue Remodelling

Because fibrosis and tissue stiffness involve several overlapping biological pathways—from oxidative stress and mitochondrial fatigue to local inflammation—researchers frequently investigate how B7-33 behaves alongside complementary peptides. Combining compounds that target distinct receptors allows laboratories to observe multi-angle tissue recovery without overloading a single cellular pathway.

One of the most logical pairings in connective tissue research combines B7-33 with BPC-157 or TB-500 (a synthetic fraction of Thymosin Beta-4). While B7-33 works through the RXFP1 receptor to clear away excessive collagen cross-linking via MMP-2 upregulation, BPC-157 and TB-500 focus on actin sequestration, endothelial cell migration, and new capillary sprouting. In a combined protocol ratio, one agent prevents the formation of rigid fibrous tissue while the others support the structural organisation of fresh, healthy extracellular matrix.

Another growing area of interest pairs B7-33 with GHK-Cu, the naturally occurring copper tripeptide. GHK-Cu modulates dozens of genes tied to skin elasticity, glycosaminoglycan synthesis, and antioxidant defence via superoxide dismutase. Evaluating B7-33 alongside GHK-Cu gives investigators a way to look at both the enzymatic breakdown of old, fibrotic matrix and the orderly deposition of fresh elastin and decorin.

Finally, tissue remodelling demands a tremendous amount of cellular energy. Fibrotic organs often suffer from sluggish mitochondrial output and poor fatty acid oxidation. For this reason, investigators studying cardiac and skeletal muscle endurance often examine RXFP1 agonists alongside metabolic regulators like slu pp 332. As an estrogen-related receptor (ERR) agonist, this compound switches on aerobic exercise genetic programmes and boosts mitochondrial respiration. Pairing a vascular and anti-fibrotic peptide like B7-33 with a mitochondrial enhancer lets researchers observe how improved blood vessel compliance and reduced tissue scarring interact with heightened cellular ATP production.

B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research

Figure: B7-33: The Non-Oncogenic Alternative for Relaxin-2 Receptor Research

Why Single-Chain Purity and TFA Removal Dictate B7-33 Stability

Even though B7-33 is much easier to manufacture than two-chain native relaxin-2, its single-chain architecture still demands strict quality control during solid-phase synthesis. Without disulphide bridges locking it into a rigid shape, the twenty-seven-amino-acid sequence of B7-33 is flexible in solution. If a synthesis batch contains truncated peptide fragments or failed deletion sequences, those malformed chains can compete for space around the RXFP1 receptor and skew pERK1/2 assay readouts.

To prevent this, any batch used for quantitative laboratory work should carry an independent certificate of analysis confirming at least 99% purity via High-Performance Liquid Chromatography (HPLC), backed by Mass Spectrometry (MS) to verify the exact molecular weight of 2987.5 Daltons. Equally important is the removal of trifluoroacetic acid (TFA). TFA is a harsh acid used to cleave peptides from their resin during manufacturing. If residual TFA salts are left behind in the lyophilised powder, they lower the pH of the liquid sample and cause cellular toxicity in delicate fibroblast and endothelial cultures. Sourcing vials that have undergone secondary salt exchange—replacing toxic TFA with benign acetate or hydrochloride ions—keeps cell viability high during sensitive MMP-2 assays.

Once the freeze-dried peptide arrives in the laboratory, proper thermal management protects its fragile sequence. Unreconstituted lyophilised vials remain stable for extended periods when stored in a freezer at minus twenty degrees Celsius away from bright light. When preparing the peptide for an experiment, allow the vial to reach room temperature before introducing a sterile bacteriostatic reconstitution solution. Trickle the liquid down the inside glass wall rather than squirting it directly onto the powder cake, and swirl gently until clear; shaking the vial creates foam and shear stress that can denature the chain. Once dissolved, store the vial in a standard laboratory refrigerator between 2°C and 8°C and complete all planned assays within two to three weeks.

Frequently Asked Questions

Why is B7-33 searched as a non-oncogenic alternative in relaxin-2 receptor research?

Researchers investigate B7-33 because it selectively activates anti-fibrotic signalling pathways without triggering the cyclic AMP production linked to tumour growth in laboratory models. Unlike native relaxin-2, this single-chain peptide only switches on specific enzymes that break down excess collagen, making it a safer focus for tissue remodelling studies.

What is the typical timeline observed in published B7-33 laboratory studies?

In preclinical models, measurable changes in cellular signalling occur within minutes, while physical tissue remodelling typically takes two to four weeks of observation. Published studies show that early enzyme activation begins quickly, but reducing established scar tissue in animal hearts or lungs requires sustained exposure over several weeks.

Can B7-33 be combined with other peptides in experimental protocols?

Yes, researchers sometimes evaluate B7-33 alongside other investigative compounds like TB-500 or BPC-157 to observe combined effects on tissue recovery. In these laboratory models, scientists analyse whether pairing an anti-fibrotic peptide with structural regeneration compounds can optimise overall cellular repair without causing unwanted receptor interference.

How should B7-33 be stored to maintain high purity for laboratory analysis?

Lyophilised B7-33 powder should be stored in a freezer at minus twenty degrees Celsius, while mixed solutions must be kept in a standard fridge. Once combined with a bacteriostatic reconstitution solution, the liquid peptide generally remains stable for up to four weeks if protected from light.

Bibliography

  • Hossain MA, Kocan M, Yao ST, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chemical Science. 2016;7(6):3805-3819. View published research
  • Marshall SA, O'Sullivan K, Ng HH, et al. B7-33 replicates the anti-fibrotic actions of serelaxin in models of cardiovascular and airway disease. British Journal of Pharmacology. 2017;174(10):1041-1054. View published research
  • Devarakonda T, Mauro AG, Guzman G, et al. B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice. Journal of the American Heart Association. 2020;9(8):e015748. View published research
  • Praveen P, Kocan M, Valkovic AL, et al. Single-chain peptide agonists of the relaxin receptors RXFP1 and RXFP2. Molecular and Cellular Endocrinology. 2019;487:34-39. View published research

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.